Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788684 · ClinicalTrials.gov registry record · Phase 1
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00788684 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 29 participants.
The verdict
NCT00788684, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 14 years after the last participant transitions with quarterly study evaluations.
Interventions
- DRUG rituximab
- DRUG ABT-263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2009-07-21 |
| Est. Completion | 2025-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788684
The ClinicalTrials.gov registry entry for NCT00788684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT00788684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788684 about?
NCT00788684 is a clinical study titled "Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers". This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 14 years after the last par...
What is the current status of trial NCT00788684?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2009-07-21. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT00788684?
The interventions under investigation include: rituximab (DRUG), ABT-263 (DRUG).
Who is sponsoring clinical trial NCT00788684?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.